Following trial failure, Favrille cuts staff

San Diego's Favrille is making massive cuts following the trial failure of Specifid announced earlier this week. The company is axing 132 of its 144 employees, including six of its eight executive officers. There was no word on which of the 12 remaining employees would be managing the company. Specifid was treatment for follicular B-cell non-Hodgkin's lymphoma. The drug failed both primary and secondary endpoints in a Phase III trial. The company's stock plunged 90 percent after the announcement on Tuesday and another 30 percent yesterday.

- see the layoff announcement
- read this report for more

Suggested Articles

In this week's EuroBiotech Report, Roche's risdiplam clears another phase 3 SMA trial, Merck KGaA spinout raises cash and Korean VCs back PDC*line.

In our EuroBiotech roundup this week, a liver disease biotech raises €11 million, Autolus offers stock and Abivax plans midphase trial. 

Merck KGaA spinout iOnctura has raised a €15 million series A round to support an early-phase solid tumor trial of a PI3Kδ inhibitor.